Ferrer takes novel antifungal into Phase III
This article was originally published in Scrip
The private Spanish pharmaceutical company Ferrer is to begin a Phase III study early next year for what it hopes will be a best–in-class topical azole antifungal, arasertaconazole, for vulvovaginal candidiasis (VVC). The fast-acting broad-spectrum antifungal product showed rapid symptom relief and significant clinical and mycological benefits when given as a single vaginal suppository in a multicentre Phase II trial, the company said.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.